文献速递内脏/肾动脉与血管畸形

博来霉素病灶内注射治疗低流量血管畸形的疗效及影响结局的因素

Intralesional injection of bleomycin in the management of low flow vascular malformations: Results and factors affecting the outcome.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2023-10-26

研究纳入50例低流量血管畸形患者,在超声和透视引导下行博来霉素病灶内注射,总体客观改善率为79.53%(静脉畸形78.05%,淋巴管畸形87.5%),81.25%患者术后超声显示尺寸缩小或完全闭塞,患者报告的疼痛、总体症状和自信心评分有统计学显著改善,弥漫性病变是唯一与客观结局不佳相关的因素,无重大并发症。

要点

  • 博来霉素病灶内注射治疗低流量血管畸形的总体客观改善率为79.53%。
  • 静脉畸形客观改善率为78.05%,淋巴管畸形为87.5%。
  • 弥漫性病变是唯一与客观结局不佳相关的因素。

核心结论

  • 博来霉素病灶内注射是低流量血管畸形的安全有效治疗方法。

研究设计与样本

  • 研究纳入50例低流量血管畸形患者,于2020年4月至2022年3月期间入组。
  • 所有患者术前接受双功超声和磁共振血管成像检查。
  • 操作在超声和透视引导下进行。
  • 评估内容包括客观改善、超声评估和患者报告结局。

主要发现

  • 总体客观改善率为79.53%,其中静脉畸形为78.05%,淋巴管畸形为87.5%。
  • 81.25%的患者术后超声显示一定程度的尺寸缩小或完全闭塞。
  • 患者报告结局分析显示疼痛、总体症状和自信心的平均评分有统计学显著改善。
  • 回归分析显示,唯一与客观结局不佳相关的因素是弥漫性病变(边界不清或累及超过一个身体区域或一个间室)。
  • 未记录到重大并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ethanol has been a commonly used sclerosant for low-flow vascular malformations, but it carries a high risk of complications. Bleomycin has been recently introduced as a potentially effective treatment. The aim of this study was to evaluate the safety and efficacy of bleomycin intralesional injection for the treatment of low-flow vascular malformations and determine the different factors affecting the outcome. PATIENTS AND METHODS: A total of fifty patients with low-flow vascular malformations were enrolled in the study between April 2020 and March 2022. All patients underwent preoperative duplex ultrasound and magnetic resonance angiography. The procedure was performed under ultrasound and fluoroscopic guidance. All patients were assessed for the objective improvement, ultrasound assessment, and patient-reported outcome. RESULTS: The overall rate of objective improvement was 79.53% (78.05% in venous and 87.5% in lymphatic malformations), whereas 81.25% of the patients showed a degree of size reduction or complete obliteration on postoperative ultrasound. The patient-reported outcome analysis showed a statistically significant improvement in the mean score for the pain, overall symptoms, and self-confidence. On regression analysis, the only factor associated with poor objective outcome was diffuse lesions (ill-defined or extending in more than one body region or one compartment). No major complications were recorded. CONCLUSIONS: Bleomycin intralesional injection is a safe and effective treatment for low-flow vascular malformations.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Abdelaty MH, Badran AI, Aborahma AM, et al. Intralesional injection of bleomycin in the management of low flow vascular malformations: Results and factors affecting the outcome. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37890586. doi:10.1016/j.jvsv.2023.101694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。